A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Overview
Authors
Affiliations
Importance: Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders.
Observations: This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option.
Conclusions And Relevance: The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.
Yermus R, Bottos J, Bryson N, De Leo J, Earleywine M, Hackenburg E Psychedelic Med (New Rochelle). 2025; 2(2):87-95.
PMID: 40051583 PMC: 11613527. DOI: 10.1089/psymed.2023.0021.
Psychedelics: Safety and Efficacy.
Miller N Int J Environ Res Public Health. 2025; 22(2).
PMID: 40003360 PMC: 11855591. DOI: 10.3390/ijerph22020134.
Gas necrosis and sepsis due to recreational ketamine use.
Bezerra A, Vazquez C, Guilherme A, Rodrigues A, Crivillari M, Queiroz W Rev Inst Med Trop Sao Paulo. 2025; 67:e9.
PMID: 39936652 PMC: 11808713. DOI: 10.1590/S1678-9946202567009.
Trends in poisonings involving ketamine in the United States, 2019-2023.
Palamar J, Jewell J, El-Shahawy O, Black J Drug Alcohol Depend. 2025; 268:112549.
PMID: 39827824 PMC: 11832312. DOI: 10.1016/j.drugalcdep.2025.112549.
Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.
Yang K, Kepner W, Cleland C, Palamar J J Affect Disord. 2025; 373:345-352.
PMID: 39746553 PMC: 11794009. DOI: 10.1016/j.jad.2024.12.108.